Filing Details

Accession Number:
0000950170-25-034607
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-03-06 16:06:05
Reporting Period:
2025-03-04
Filing Date:
2025-03-06
Accepted Time:
2025-03-06 16:06:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1726096 Richard Daniell C/O Teva Pharmaceutical Industries Ltd.
124 Dvora Hanevi'A St.,
Tel Aviv L3 6944020
Exec. Vp, European Commercial No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2025-03-04 33,512 $0.00 33,512 No 4 M Direct
Ordinary Shares Disposition 2025-03-04 21,870 $15.73 11,641 No 4 S Direct
Ordinary Shares Disposition 2025-03-05 11,641 $15.91 0 No 4 S Direct
Ordinary Shares Acquisiton 2025-03-04 20,461 $0.00 20,461 No 4 M Direct
Ordinary Shares Disposition 2025-03-04 13,353 $15.73 7,108 No 4 S Direct
Ordinary Shares Disposition 2025-03-05 7,108 $15.91 0 No 4 S Direct
Ordinary Shares Acquisiton 2025-03-04 183,169 $0.00 183,169 No 4 M Direct
Ordinary Shares Disposition 2025-03-04 56,385 $15.73 126,784 No 4 S Direct
Ordinary Shares Disposition 2025-03-05 30,015 $15.91 96,769 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2025-03-04 33,512 $0.00 33,512 $0.00
Ordinary Shares Restricted Share Units Disposition 2025-03-04 20,461 $0.00 20,461 $0.00
Ordinary Shares Restricted Share Units Disposition 2025-03-04 183,169 $0.00 183,169 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
33,512 No 4 M Direct
61,384 No 4 M Direct
0 No 4 M Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  7. Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.
  8. Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.
  9. Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.